Biomea Fusion pushes BMF-650 Phase I data to October 2026
The company filed an 8-K revising its expected timeline for topline results from the Phase I GLP-131 study of obesity candidate BMF-650.
Biomea Fusion, Inc. disclosed in a Form 8-K dated September 22, 2026 that it has revised the expected timing for data from its Phase I trial of BMF-650. The trial, known as GLP-131, is testing BMF-650 in obese, otherwise healthy volunteers, and the company now expects topline results in October 2026.1
The filing does not disclose what the previous timeline estimate was or provide further detail on trial design, dosing, or enrollment.
The 8-K was signed by Michael J.M. Hitchcock, identified in the filing as Interim Chief Executive Officer, Director (Principal Executive Officer)1 of the company.
Biomea Fusion is listed on The Nasdaq Global Select Market1 under the ticker symbol BMEA1, with its principal executive offices located in San Carlos, California1.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.